Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

[1]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[2]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[3]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[4]  Olivier Salvado,et al.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.

[5]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[6]  C. Rowe,et al.  Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.

[7]  E. Siemers,et al.  Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid &bgr; Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease , 2012, Clinical neuropharmacology.

[8]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[9]  Andrei G. Vlassenko,et al.  Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.

[10]  Victor L. Villemagne,et al.  Brain Amyloid Imaging , 2011, The Journal of Nuclear Medicine.

[11]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[12]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[13]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[14]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[15]  R. Pietrzak,et al.  Intra-Individual Variability in Alzheimer's Disease and Cognitive Aging: Definitions, Context, and Effect Sizes , 2011, PloS one.

[16]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[17]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[18]  C. Jack,et al.  Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.

[19]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[20]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[21]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[22]  S Ourselin,et al.  β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.

[23]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[24]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[25]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[26]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[27]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[28]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[29]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[30]  A. Toga,et al.  The Alzheimer's disease neuroimaging initiative. , 2005, Neuroimaging clinics of North America.

[31]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[32]  M Greiner,et al.  A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. , 1995, Journal of immunological methods.

[33]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[34]  C. Rowe,et al.  Rapid decline in episodic memory in healthy older adults with high amyloid-β. , 2013, Journal of Alzheimer's disease : JAD.

[35]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[36]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .